GET DAILY SIGNALSElutia (ELUT) Reports +20.4% Revenue Growth in Q3 Amid Strategic Shift
Key Takeaways
- Net sales from continuing operations rose 20.4% year over year to $1.1 million, led by 20% growth in the cardiovascular business.
- Total net loss narrowed to $1.3 million, or $0.03 per basic share, from $3.9 million a year earlier, helped by $5.2 million in income from discontinued operations.
- Loss from operations widened to $6.9 million, reflecting a $1.9 million increase in research and development (R&D) spending on the NXT-41 and NXT-41x programs.
- Elutia secured $26 million in non-dilutive capital across three completed funding catalysts and ended the quarter with $29.1 million in cash, excluding an $8 million Boston Scientific holdback received October 1.
- Management plans to submit NXT-41x to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026, with an FDA clearance decision on NXT-41 expected this quarter.
Putting the Earnings in Context
Elutia is in the middle of a strategic transformation into a pure-play drug-eluting biomatrix company focused on surgical reconstruction. Following the sale of its SimpliDerm business in August, the third quarter offered investors a clearer view of the leaner, cardiovascular-and-pipeline-focused company that remains. The report matters less for its headline revenue than for what it signals about Elutia’s two critical near-term drivers: regulatory progress on its NXT-41 and NXT-41x programs and the strength of its cash position. With a $1.5 billion U.S. breast reconstruction market in view, investors are closely watching whether Elutia can fund itself without diluting shareholders while advancing its lead product toward FDA clearance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Q3 Results Breakdown
For the third quarter ended September 30, 2026, Elutia reported net sales from continuing operations of $1.1 million, up 20.4% from $0.9 million a year earlier. Gross margin on a GAAP basis improved to 61.7% from 52.8%, while adjusted gross margin, which excludes non-cash amortization of intangibles, reached 85.5% compared with 81.3%.
Total operating expenses increased to $7.6 million from $6.4 million, driven by $1.9 million of additional R&D spending on NXT-41 and NXT-41x, partially offset by a $0.7 million reduction in net litigation costs. Loss from operations widened to $6.9 million from $5.9 million, and net loss from continuing operations was $6.5 million, compared with $1.0 million in the prior-year period, which had benefited from a $5.1 million non-cash warrant revaluation gain. Adjusted EBITDA was a loss of $5.6 million, versus a loss of $3.4 million a year earlier.
On a total-company basis, income from discontinued operations of $5.2 million narrowed the net loss to $1.3 million, or $0.03 per basic share, from $3.9 million, or $0.09 per basic share, a year ago. Revenue came in below consensus expectations, which had reflected now-divested SimpliDerm sales, while the reported loss per share was narrower than the consensus estimate. Elutia ended the quarter with $29.1 million in cash and cash equivalents. From what I see, the cardiovascular segment’s 20% growth stands out as a positive signal here.
Market Reaction and Investor Sentiment
Elutia’s earnings were not a single-line story. The headline revenue figure of $1.1 million fell well short of the roughly $3.0 million consensus, but much of that gap reflects the mid-quarter divestiture of SimpliDerm, which shifted that revenue into discontinued operations. At the same time, the reported loss per share was meaningfully narrower than the consensus estimate of about $0.13 to $0.15, helped by income from the divested business. Investors appear to be weighing these accounting-driven movements against the more durable positives: a strengthened balance sheet, reduced litigation costs, and clearer visibility into the NXT-41 and NXT-41x regulatory timeline. Sentiment remains focused on execution risk around FDA clearance and Elutia’s ability to preserve its runway without further equity dilution. I’m watching this closely as the market digests the numbers.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most important near-term catalyst is regulatory. Elutia expects an FDA clearance decision on NXT-41 during the current quarter and plans to submit NXT-41x to the agency in the fourth quarter of 2026, with a clearance decision anticipated in the first half of 2027. Investors should monitor the timing and outcome of both steps, since clearance would validate the company’s drug-eluting biomatrix platform ahead of a commercial launch.
Funding remains a second focal point. The company completed three funding catalysts in just over seven weeks—a $15 million loan facility with Avenue Capital Group, the $8 million SimpliDerm sale to Cellution Biologics, and the $8 million Boston Scientific holdback—adding $26 million without an equity offering. Additional capital sources include a $5 million second tranche from Avenue Capital, up to $3 million in SimpliDerm milestone payments, and a potential sale of the cardiovascular business.
Finally, investors should watch operating trends in the cardiovascular segment, which grew revenue 20% year over year with an 85% adjusted gross margin, and any updates on the strategic divestiture process. Cost discipline and the pace of R&D investment will also shape how far the current cash runway extends as Elutia prepares for a potential commercial launch of NXT-41x.
Using AI Tools in My Research
In my own analysis workflow, I frequently rely on Tickeron’s AI Screener to quickly filter for stocks with similar fundamentals and technical setups. It helps surface comparable names in the medical technology space and highlights potential patterns I might otherwise miss during earnings season. The tool has become a regular part of how I cross-check ideas before diving deeper into company filings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ELUT saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for ELUT moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 48 similar instances where the indicator exited the overbought zone. In 45 of the 48 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ELUT as a result. In 97 of 110 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ELUT turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 43 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
ELUT moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELUT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
Following a +5.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELUT advanced for three days, in 199 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
ELUT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 138 of 155 cases where ELUT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.112) is normal, around the industry mean (4.338). P/E Ratio (0.587) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.028) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. ELUT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELUT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement